Depression can be difficult in ways that are not always visible from the outside. You may have taken medication faithfully, attended therapy, made changes that required real effort, and still find that the heaviness remains. When that happens, it is natural to ask whether your depression is treatment-resistant, and what that phrase actually means.
At Tri-Cities Infusion and Wellness Clinic, we believe the next step should begin with a careful look backward. A label can be useful, but it should never replace the fuller story of what you have tried, what changed, what did not, and what your life has been like along the way.
Treatment-resistant depression is a clinical description, not a self-diagnosis
Treatment-resistant depression, often called TRD, generally describes major depression that has not improved enough after appropriate treatment attempts. A commonly used working definition involves inadequate response to at least two antidepressant trials of adequate dose and duration, although there is no single definition that captures every clinical circumstance. A review of how TRD is defined notes that the term has meaningful variations across research and clinical settings (Gaynes et al., 2020).
That distinction matters. Two people may both say, “Medication did not work,” while their histories are quite different. One may have stopped a medication after difficult side effects. Another may have tried several medications at therapeutic doses for sufficient periods. A third may have had depression symptoms shaped by an unrecognized medical issue, substance use, trauma, grief, bipolar-spectrum symptoms, or another mental health condition.
So, treatment resistance is not a verdict about you or your effort. It is a clinical question. It asks whether prior treatment trials were truly adequate, whether the diagnosis needs another look, and what options deserve thoughtful consideration now. For a closer look at treatment-resistant depression, we encourage patients to begin with the details rather than the label alone.
What we review before calling a treatment trial unsuccessful
A medication that was prescribed is not necessarily a medication that had a fair chance to help. During an individualized assessment, we review the practical and clinical context around each prior treatment.
Dose, duration, and consistency
Many antidepressants need time, and sometimes dose adjustments, before a clinician can reasonably evaluate their effect. We look at how long you took the medication, whether the dose reached a therapeutic range when appropriate, and whether missed doses, access barriers, or side effects made consistency difficult.
We also ask what “not working” meant in your day-to-day experience. Did sleep improve but motivation remain absent? Did anxiety lessen while low mood persisted? Did you feel some benefit, then lose it? Depression is not a single symptom, and response is not always all or nothing.
Side effects and tolerability
A medication that causes intolerable side effects may be impossible to continue, even if it offers partial symptom relief. That is clinically important. Tolerability is not a minor footnote in treatment history. It helps determine whether a prior approach was practical and sustainable for you.
We want to understand the full picture, including emotional blunting, sleep disruption, appetite changes, sexual side effects, agitation, physical discomfort, or other concerns that affected your ability to stay with treatment. A plan has to fit a real person living a real life.
Therapy and other forms of support
Medication history is only one part of the assessment. We may discuss prior psychotherapy, the type of therapy, consistency of attendance, stress at home or work, sleep, substance use, social support, and medical care. None of these questions are meant to assign blame. They help us see what may be maintaining symptoms and what support may be missing.
Research continues to describe TRD as a complex condition that requires attention to diagnostic accuracy, treatment adequacy, co-occurring conditions, and individualized planning, rather than a simple count of failed prescriptions. A contemporary review of TRD management emphasizes this broader clinical assessment (McIntyre et al., 2023).
Why diagnosis deserves a second look
Sometimes depression is depression. Sometimes the symptoms that appear to be depression are part of a more complicated clinical picture. Before considering a next step, we may ask about past periods of unusually elevated energy, reduced need for sleep, impulsivity, racing thoughts, or mood shifts that could suggest bipolar-spectrum illness. Treatment-resistant bipolar depression is assessed differently from major depressive disorder, and the distinction can affect care decisions. Guidance on resistant bipolar depression highlights the importance of defining that condition carefully (Vieta et al., 2025).
We also review anxiety, obsessive thoughts or compulsions, trauma symptoms, chronic pain, attention concerns, and medical factors. Depression can overlap with many experiences. A careful assessment may clarify whether symptoms are being treated at their source, or whether another factor needs direct attention alongside them.
This is why we do not assume that a long treatment history automatically points to one answer. We listen for patterns. We review current medications and health history. We make room for the details that can get lost when someone has been trying to feel better for a long time.
The next step is not always one thing
When depression has not responded adequately, clinicians may consider several evidence-informed paths. Depending on the person, these can include changing medication strategies, adding an adjunctive medication, revisiting psychotherapy, considering neurostimulation, or seeking a higher level of psychiatric support. Research on augmentation approaches reflects the range of medication-based strategies clinicians may evaluate (Nuñez et al., 2022).
Electroconvulsive therapy, or ECT, is also an established treatment clinicians may consider in certain severe or urgent circumstances, particularly when rapid intervention is needed. A review of ECT in TRD describes its continuing role within treatment-resistant depression care (Hsieh, 2023).
At our clinic, we also offer IV ketamine treatment. Ketamine for depression is an off-label use, meaning the FDA has not approved ketamine specifically for depression, even though clinicians may prescribe it off-label when they determine it is medically appropriate. It is not appropriate for every person with prior treatment nonresponse, and a history of depression alone does not establish candidacy.
If ketamine is part of the conversation, we discuss your health history, medications, prior responses, risks, expectations, and safety considerations in a controlled clinical setting. You can read more about ketamine infusion therapy and the essential facts about infusions before a consultation.
Questions we hear from patients
Does one antidepressant that did not help mean I have TRD?
Usually, no. One unsuccessful medication trial can be discouraging, but treatment-resistant depression is generally considered after multiple adequate treatment attempts. Your clinician will consider the dose, duration, adherence, side effects, diagnosis, and symptom course rather than relying on a number alone.
What if I could not tolerate a medication?
Tell us exactly what happened. Side effects can make a medication trial incomplete, but they remain important information. They may help guide what should be avoided, adjusted, or monitored in the future.
Does TRD mean I will never feel better?
No. The term describes past response to treatment, not your future. It can help create a more focused conversation about options, while leaving room for careful assessment and an individualized plan.
How do I prepare for an appointment?
Bring a list of current and past medications if possible, including approximate dose, duration, benefits, and side effects. Notes from therapy, psychiatric care, hospitalizations, major life events, and medical diagnoses can also be helpful. You do not need to organize everything perfectly. We can work through it together.
Key takeaways to carry with you
TRD usually refers to depression that has not responded adequately to multiple appropriate treatment trials.
The quality of each prior trial matters, including medication dose, duration, adherence, benefit, and tolerability.
A second look at diagnosis, co-occurring conditions, and life circumstances is often an essential part of the evaluation.
Treatment resistance does not mean you have failed, nor does it determine what will happen next.
Ketamine for depression is off-label and requires an individualized clinical assessment.
A measured next conversation
When depression has persisted through treatment, it can feel as though every appointment asks you to start over. We approach that history differently. We want to understand it, including what has been hard, what has helped even slightly, and what has not yet been explored with enough care.
Our Kennewick team includes anesthesia-trained providers who review medical history, current medications, and prior treatment response before discussing IV ketamine treatment. You may also find it useful to review the benefits of ketamine-assisted care and the common questions you might have. When you are ready, call us at (509) 383-8760 to schedule a conversation about your history and whether an evaluation is appropriate.
About our providers
Tri-Cities Infusion and Wellness Clinic is led by Tyler Thornock, ARNP, CRNA, and Ben Clark, CRNA. Michelle Perez, NP, and Angela Shaw, NP, round out our clinical team. Together, we provide individualized, patient-centered care in Kennewick, with attention to your medical history, current symptoms, prior treatment experiences, and safety.
Medical disclaimer
This article is for educational purposes and is not medical advice. A qualified clinician should evaluate depression symptoms and treatment options based on your individual health history. If you are in immediate danger, have thoughts of harming yourself, or need urgent emotional support, call or text 988 to reach the 988 Suicide and Crisis Lifeline, call 911, or go to the nearest emergency department.
Works Cited
1. Gaynes BN, et al. Defining treatment-resistant depression. https://pubmed.ncbi.nlm.nih.gov/31638723/
2. McIntyre RS, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. https://pubmed.ncbi.nlm.nih.gov/37713549/
3. Vieta E, et al. Defining Treatment-Resistant Bipolar Depression: Recommendations From the ISBD Task Force. https://pubmed.ncbi.nlm.nih.gov/40808269/
4. Nuñez NA, et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. https://pubmed.ncbi.nlm.nih.gov/34986373/
5. Hsieh MH. Electroconvulsive therapy for treatment-resistant depression. https://pubmed.ncbi.nlm.nih.gov/37806717/
6. 988 Suicide and Crisis Lifeline. https://988lifeline.org/
Disclaimer
This article is for educational purposes only and is not a substitute for individualized evaluation, diagnosis, or treatment from a qualified healthcare professional.
